...
首页> 外文期刊>Bioorganic and medicinal chemistry >Ligand design for alpha1 adrenoceptor subtype selective antagonists.
【24h】

Ligand design for alpha1 adrenoceptor subtype selective antagonists.

机译:alpha1肾上腺素受体亚型选择性拮抗剂的配体设计。

获取原文
获取原文并翻译 | 示例

摘要

Alpha1 adrenoceptors have three subtypes and drugs interacting selectively with these subtypes could be useful in the treatment of a variety of diseases. In order to gain an insight into the structural principles governing subtype selectivity, ligand based drug design (pharmacophore development) methods have been used to design a novel 1,2,3-thiadiazole ring D analogue of the aporphine system. Synthesis and testing of this compound as a ligand on cloned and expressed human alpha1 adrenoceptors is described. Low binding affinity was found, possibly due to an unfavourable electrostatic potential distribution. Pharmacophore models for antagonists at the three adrenoceptor sites (alpha1A, alpha1B, alpha1D) were generated from a number of different training sets and their value for the design of new selective antagonists discussed. The first preliminary antagonist pharmacophore model for the alpha1D adrenoceptor subtype is also reported.
机译:Alpha1肾上腺素能受体具有三种亚型,与这些亚型选择性相互作用的药物可用于治疗多种疾病。为了深入了解控制亚型选择性的结构原理,已使用基于配体的药物设计(药效团开发)方法来设计新颖的1,2,3-噻二唑环D类似物的阿芬啡。描述了该化合物作为配体在克隆和表达的人α1肾上腺素受体上的合成和测试。发现低的结合亲和力,可能归因于不利的静电势分布。在许多不同的训练集上生成了三个肾上腺素能受体部位(α1A,α1B,α1D)拮抗剂的药理模型,它们对设计新的选择性拮抗剂具有重要的意义。还报道了α1D肾上腺素受体亚型的第一个初步的拮抗剂药效团模型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号